Clinical Trial Update: IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor [Phase 1]

View source ↗

Summary

Phase 1 trial of AB-218, an IDH1 inhibitor, in advanced IDH1-mutant cholangiocarcinoma and other IDH1-mutant solid tumors has been terminated. The update indica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• AB-218

Snippet

Sponsor: AnHeart Therapeutics Inc. | Conditions: Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation | Phase 1 | Status: TERMINATED